Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Pancreatic cancer RNA vaccine shows durable T cell immunity

2.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

3.

Exercise can counter detrimental effects of cancer treatment, review suggests

4.

In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.

5.

Survivors of high-risk neuroblastoma face substantial late effects of modern therapies


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot